Updated on 22 May 2012
"We are delighted to have the opportunity to collaborate with Xiangxue Pharmaceuticals to develop KX02. We are impressed by the high scientific standards of their research team and advisors, as well as the management team's strong commitment to research and development. Kinex will benefit from the scientific and local experience of Xiangxue Pharmaceuticals in the global development of KX02," states Dr Johnson Yiu-Nam Lau, chairman and CEO, Kinex Pharmaceuticals.
"The collaboration with Xiangxue Pharmaceuticals will allow us to accelerate the clinical development of KX02. I am delighted to have the opportunity to work closely with their clinical development team." stated Dr Rudolf Kwan, Chief Medical Officer, Kinex Pharmaceuticals. Dr Kwan was formerly VP of Clinical Research at Schering-Plough Research Institute.